RECCE PHARMACEUTICALS LTD — Director's Dealing 2018

Apr 26, 2018

Appendix 3X Initial Director’s Interest Notice

Rule 3.19A.1

Appendix 3X

Initial Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/9/2001.

Name of entity	Recce Pharmaceuticals Ltd
ABN	73 124 849 065

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of DirectorDate of appointment	Dr John Prendergast
	23 April 2018

Part 1 - Director’s relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust.

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Number & class of securities

Nil

• See chapter 19 for defined terms.

Appendix 3X Page 1

11/3/2002

Appendix 3X Initial Director’s Interest Notice

Part 2 – Director’s relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust.

Name of holder & nature of	Number & class of Securities
interest
Note: Provide details of the circumstances giving rise to	Nil
the relevant interest.

Part 3 – Director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	Under the terms contained in Dr Prendergast’s letter of
	appointment with Recce Pharmaceuticals Ltd, Dr
	Prendergast receives AUD$50,000 per annum (plus
	applicable superannuation) and an allocation of shares
	as remuneration for his services. The issue of shares is
	subject to shareholder approval at the next Annual
	General Meeting (AGM).
Nature of interest	Subject to shareholder approval being obtained at the
	AGM, Dr Prendergast will receive an allocation of
	250,000 fully paid ordinary shares as part of his
	remuneration for his services.
Name of registered holder	N/A
(if issued securities)
No. and class of securities to	250,000 fully paid ordinary shares (subject to
which interest relates	shareholder approval being obtained at the AGM).

• See chapter 19 for defined terms.

Appendix 3X Page 2

11/3/2002